Introduction: PRRT with 90Y-octreotide (Y) and 177Lu-octreotate (Lu) is well-tolerated.
Aim(s): To identify clinical parameters predictive of long-term renal and hematological toxicity.
Materials and methods: Eight-hundred and seven patients from IEO-Milan (1997-2013). Seven-hundred and ninety-three (98%) with Lu, Y or both (Lu: 34.4%, Y: 44.4%, Lu+Y: 19.5%), 2% combinations of PRRT + other agents. Follow-up: 30 months (1-180). Parameters included renal and marrow risk factors. Analysis: multiple regression, modeling.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Lisa Bodei
To read results and conclusion, please login ...
Further abstracts you may be interested in